Intermittent fasting versus continuous calorie energy reduction in prostate cancer patients on active surveillance
Yeary KHK, Yu H, Hussein AA, Varady K, DiCarlo E, Escaldi A, Tang L
Translational behavioral medicine · 0 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Roswell Park Cancer Institute
- Universidad u hospital
- Roswell Park Alliance Foundation, Roswell Park Comprehensive Cancer Center
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-01-01 · Transl Behav Med · vol. 16 · número 1
- Editorial
- Oxford University Press
- Citado
- 0 citas · más que el 80% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 50 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Nutritional Studies and Diet · Obesity, Physical Activity, Diet
- Palabras clave
- intermittent fasting, 5:2 diet, continuous energy restriction, prostate cancer, active surveillance, weight loss, obesity, behavioral weight loss, feasibility, glycolipid metabolism, inflammation, immune function, tumor progression markers
- MeSH
- humans, prostatic neoplasms, obesity, weight loss, caloric restriction, feasibility studies, aged, middle aged, male, watchful waiting, intermittent fasting
7 autores
- Karen Hye‐cheon Kim Yeary🇺🇸Roswell Park Comprehensive Cancer Center
- Han Yu🇺🇸Roswell Park Comprehensive Cancer Center
- Ahmed Aly Hussein🇺🇸Roswell Park Comprehensive Cancer Center
- Krista A Varady🇺🇸University of Illinois Chicago
- Elizabeth DiCarlo🇺🇸Roswell Park Comprehensive Cancer Center
- Allison Escaldi🇺🇸Roswell Park Comprehensive Cancer Center
- Li Tang🇺🇸Roswell Park Comprehensive Cancer Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Prostate cancer (PCa) is the most common cancer in US men. Nearly half of those diagnosed with PCa present with low-risk disease based on clinical guidelines, for which active surveillance (AS) is increasingly recommended by clinicians to avoid invasive treatment. Obesity is a well-recognized risk factor for poor PCa prognosis. Yet weight loss interventions for PCa patients on AS are limited.
Purpose
Using the NIH Stage Model for Behavioral Intervention Development as a guide, our Stage 1 study translated and assessed the feasibility, estimated preliminary efficacy signals, and conducted exploratory analyses of two evidence-based behavioral weight loss interventions for PCa patients on AS.
Methods
We worked with patients to translate evidence-based continuous energy restriction (CER) and 5:2 (two 600 kcal fast days, eat normally 5 days) intermittent fasting (IF) interventions for PCa patients on AS. Feasibility, estimated preliminary efficacy signals, and exploratory analyses on outcomes from baseline to 3 and 6 months was assessed using a parallel arm randomized controlled trial.
Results
The study met the pre-established benchmarks for feasibility. Twenty patients were randomized (10 CER, 10 IF). All were retained over 6-month follow-up. Participants were predominantly White (95%), with an average age of 65.9 (SD 8.45) years. Each arm produced clinically meaningful weight loss from baseline to 6 months (CER -5.79% [95% confidence interval, CI: -3.48, -8.09; P < .01); IF -7.50% (95% CI: -5.19, -9.80; P < .01). Within IF only, there were favorable exploratory changes in biomarkers related to lipid and glucose metabolism, inflammation and immune function, and signaling pathways critical for PCa progression.
Conclusions
Our study provides evidence for our interventions' feasibility and preliminary efficacy signals for clinically meaningful weight loss in PCa patients on AS. Future studies examining weight loss' impact on PCa progression and related biomarkers are needed.
Clinical trial information
The Clinical Trials Registration NCT05764330.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.